Vulvar DiseasesVdiNNCT05890092
Vulvar Disease in Nigeria Observational Study
An observational study of Vulvar Diseases and Vulvar Atrophy, run by KDRS ltd at 1 site in United Kingdom.
Trial summary
Vulvar disease in Nigeria A look at awareness within patients and health practitioners, self-reported and actual prevalence within communities in Nigeria Read more about this study
- Who is it for?
- Ages 10 to 90 years, women only
- Conditions the study is for
- Vulvar Diseases, Vulvar Atrophy, Dermatoses
- What is being tested?
- Observation
- How many people
- 1,000 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- 3 May 2023to 30 Nov 2026
- How long will I take part?
- 12 Months
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 10 to 90 years
- Women only
- Child, Adult, Older adult
Study population: All afab, willing to participate in the study.
Who may be able to join
- biological females - afab
Who cannot join
- none-afab
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United Kingdom1 site, 1 recruiting
- Recruiting
Kdrs
London, Rm166el
Lead Research officer, 00447984470726, towales1@gmail.com
Dr Adedipe, MRCOG
About this study
Official title: Vulvar Disease in Nigeria - Registry ( Observationsl Study)
Vulvar disease in Nigeria A look at awareness within patients and health practitioners, self-reported and actual prevalence within communities in Nigeria
- Conditions
- Vulvar Diseases, Vulvar Atrophy, Dermatoses
- Being tested
- Observation
- Medical subject headings
- Vulvar Diseases, Skin Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
ObservationOther
Observing for disease prevalence - actual and self-reported
What is being measured
The primary outcome is the main question the study is designed to answer.
Prevalence of Vulvar disease
Awareness of Vulvar disease (descriptor)
Measured: 1-12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Jun 2023
- Study start3 May 2023
- Primary completion2 May 2026 (estimated)
- Study completion30 Nov 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Vulvar DiseasesStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Prospective
- Enrolment
- 1,000 participants (estimated)
- Target duration
- 12 Months
Sponsor and investigators
- Lead sponsor
- KDRS ltd
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05890092
- Sponsor's protocol ID
- KDRS-NGR001
- Acronym
- VdiN
- Status last verified
- May 2023
- First submitted
- 25 May 2023
- Last updated
- 6 Jun 2023
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 6 Jun 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Vulvar Disease in Nigeria - Registry ( Observationsl Study)
- ClinicalTrials.gov ID
- NCT05890092
- Acronym / sponsor ID
- VdiN / KDRS-NGR001
- Conditions
- Vulvar Diseases, Vulvar Atrophy, Dermatoses
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 1,000 participants (estimated)
- Lead sponsor
- KDRS ltdIndustry (pharma, biotech, devices)
- Study start
- 3 May 2023 (actual)
- Primary completion
- 2 May 2026 (estimated)
- Study completion
- 30 Nov 2026 (estimated)
- First posted
- 6 Jun 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Vulvar disease in Nigeria A look at awareness within patients and health practitioners, self-reported and actual prevalence within communities in Nigeria
Study design
- Observational model
- Other
- Time perspective
- Prospective
- Target follow-up
- 12 Months
Who may qualify
- Ages
- 10 to 90 years
- Sex
- Female only
- Age groups
- Child, Adult, Older adult
- Study population
- All afab, willing to participate in the study.
Key inclusion criteria (1 listed)
- biological females - afab
Key exclusion criteria (1 listed)
- none-afab
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| ObservationObserving for disease prevalence - actual and self-reported | Other | – |
Primary outcome
Prevalence of Vulvar disease
Time frame: 1-12 months
Awareness of Vulvar disease (descriptor)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Jun 2023.
- Individual participant dataSharing planned: Undecided
Related trials for Vulvar Diseases
RecruitingObservational study
InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer
Cancer Risk, Cancer Predisposition Syndrome
Active, not recruitingPhase 2
Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers
Anaplastic Large Cell Lymphoma, ALK-Negative, Anaplastic Large Cell Lymphoma, ALK-Positive
RecruitingPhase 1/2
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
Advanced Solid Tumors, Genital Neoplasm, Female
RecruitingObservational study
Large Algorithm Setting and Validation Study
Bacterial Infections, Bacterial Infections and Mycoses
Active, not recruitingPhase 2
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Acinar Cell Carcinoma, Adenoid Cystic Carcinoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Vulvar Diseases and Vulvar Atrophy, run by KDRS ltd at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 6 Jun 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Prevalence of Vulvar disease (time frame: 1-12 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Jun 2023; AzTrials last refreshed its copy on 5 Nov 2026.